Isofol Medical AB (publ)

Stockholm Stock Exchange ISOFOL.ST

Isofol Medical AB (publ) Revenue Per Share for the year ending December 31, 2023: USD 0.00

Isofol Medical AB (publ) Revenue Per Share is USD 0.00 for the year ending December 31, 2023, a -94.18% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Isofol Medical AB (publ) Revenue Per Share for the year ending December 31, 2022 was USD 0.01, a -61.46% change year over year.
Isofol Medical AB (publ) Revenue Per Share for the year ending December 31, 2021 was USD 0.02, a -66.06% change year over year.
Isofol Medical AB (publ) Revenue Per Share for the year ending December 31, 2020 was USD 0.06, a 0.00% change year over year.
Isofol Medical AB (publ) Revenue Per Share for the year ending December 31, 2019 was USD 0.00, a 0.00% change year over year.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

Stockholm Stock Exchange: ISOFOL.ST

Isofol Medical AB (publ)

CEO	Mr. Petter Segelman Lindqvist
IPO Date	April 4, 2017
Location	Sweden
Headquarters	Biotech Center
Employees	4
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.

Key trends

Past 5 years